## 第三届中肽全球多肽新药研发会议 The Third CPC Symposium on Peptide Therapeutics







### THE THIRD CPC SYMPOSIUM ON PEPTIDE THERAPEUTICS

October 28-30, 2015, Hangzhou, China

The Third CPC Symposium on Peptide Therapeutics continues the successful tradition of the conferences hosted by Chinese Peptide Company (CPC) from previous years. The symposium offers a forum for scientific discussions of recent developments in the exciting field of peptide therapeutics and features lectures on a broad range of topics including new technologies, drug discovery, CMC, and clinical developments in the field. The programs will be organized into four different sections:

- \* Session one: Overview and perspectives of peptide therapeutics
- \* Session two: Peptide-based drug discovery and new technologies
- \* Session three: Manufacturing and analytical development for peptide therapeutics
- \* Session four: Peptide-based therapeutics in clinical development

In addition, the symposium will have two discussion panels led by experts from the fields. The first panel will feature FDA and CFDA reviewing experts to discuss evolving regulatory environments for drug industry. The second panel consisting of ranking VC/PE institutions will discuss investment dynamics in the drug industry and help participants connect directly with investment community for capital needs.

Hangzhou is renowned for its rich culture, historic relics and natural beauty. It has been known as one of the most scenic cities in China for much of the last 1,000 years. Late October, when cool, clear autumn days converge with our rich heritage, is one of the best times to visit this beautiful city. We hope you can join us and look forward to welcoming you in Hangzhou!

### 第三届中肽全球多肽新药研发会议 The Third CPC Symposium on Peptide Therapeutics

第三届中肽全球多肽新药研发会议(THE THIRD CPC SYMPOSIUM ON PEPTIDE THERAPEUTICS)将于2015年10月28日到30日在杭州和达 希尔顿逸林酒店召开,本次会议围绕多肽药物研发展开四大主题,盛邀全 球知名多肽药物研发企业领袖、CFDA以及FDA官员和专家、知名中国生 物制药领域风投机构等出席,预计参会人员达150至200人。大会期间, 除了论坛主题之外,还有更多互动和精彩内容,包括多肽类新药注册以及 当前生物行业投资方向与前景专题讨论,一对一合作洽谈、以及新药申报 政策与项目融资咨询等。

- \* 主题一:多肽药物发展及前景概览
- \* 主题二:多肽新药研发和新技术
- \* 主题三:多肽药物的GMP生产、质量研究及申报
- \* 主题四:多肽药物临床案例分享

此外,为支持、表彰青年学生在新药研发领域优异的学术表现,大会特别开设"杰出学生研究奖",以激励更多优秀人才投身中国多肽事业。

中肽全球多肽新药研发会议锻造专业平台,致力于增强多肽新药研发领域提供专业交流与探索合作。

期待与您相逢杭州金秋,共探多肽新药未来。





#### Day One, Wednesday, October 28, 2015

8:00-9:00 am	Registration			
SESSION 1	Overview and perspectives of peptide therapeutics			
9:00 am	Welcome Shawn Lee, Ph.D., Chairman, <i>Chinese Peptide Company</i>			
9:10 am	<b>What's next for gut peptide therapeutics?</b> Richard Pittner, Ph.D., Sr. VP, <i>Haiding Pharmaceuticals (former Sr. Director, External Research, Lilly and Pfizer), USA</i>			
9:50 am	<b>Peptide therapeutics: Overcoming challenges for developing</b> <b>commercially successful medicine</b> Ved Srivastava, Ph.D. Co-Founder, <i>PHoundry Pharmaceuticals (Former Head of</i> <i>Peptide Chemistry at GSK), USA</i>			
10:30 am	Coffee break			
10:45 am	<b>Regulatory considerations on the development of peptide drug products in US</b> Duu-Gong Wu, Ph.D., Director/Senior Consultant, PPD Regulatory Consulting, (former US FDA/CDER Deputy Division Director, Chemistry Division II)			
11:25 am	<b>VC/PE panel discussion</b> Panel member: Yi Shi, Ph.D., General Manager, <i>Lilly Asian Venture</i> ; Li Xie (谢力), President, <i>HaiBang Venture (</i> 海邦投资), others TBD			
12:30-2:00 pm	Lunch break			
SESSION 2	Peptide-based drug discovery and new technologies			
<b>SESSION 2</b> 2:00 pm	Peptide-based drug discovery and new technologiesThe application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of Peptide Group, Genentech, USA			
	The application of peptides for medical imaging			
2:00 pm	The application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of <i>Peptide Group, Genentech, USA</i> Fluorescent-labeled peptides for diagnostic imaging			
2:00 pm 2:30 pm	The application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of Peptide Group, Genentech, USAFluorescent-labeled peptides for diagnostic imaging Thomas D. Wang, Ph.D., Professor, University of Michigan, USADevelopment of novel non-aqueous formulation of synthetic glucagon for the treatment of hypoglycemia			
2:00 pm 2:30 pm 3:00 pm	The application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of Peptide Group, Genentech, USAFluorescent-labeled peptides for diagnostic imaging Thomas D. Wang, Ph.D., Professor, University of Michigan, USADevelopment of novel non-aqueous formulation of synthetic glucagon for the treatment of hypoglycemia Steve Prestrelski, Ph.D., CSO, Xeris Pharmaceuticals, USA			
2:00 pm 2:30 pm 3:00 pm 3:30 pm	The application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of Peptide Group, Genentech, USAFluorescent-labeled peptides for diagnostic imaging Thomas D. Wang, Ph.D., Professor, University of Michigan, USADevelopment of novel non-aqueous formulation of synthetic glucagon for the treatment of hypoglycemia Steve Prestrelski, Ph.D., CSO, Xeris Pharmaceuticals, USACoffee breakSynthetic D-proteins as pharmaceutical products			
2:00 pm 2:30 pm 3:00 pm 3:30 pm 3:45 pm	The application of peptides for medical imaging Kurt Deshayes, Ph.D., Head of Peptide Group, Genentech, USAFluorescent-labeled peptides for diagnostic imaging Thomas D. Wang, Ph.D., Professor, University of Michigan, USADevelopment of novel non-aqueous formulation of synthetic glucagon for the treatment of hypoglycemia Steve Prestrelski, Ph.D., CSO, Xeris Pharmaceuticals, USACoffee breakSynthetic D-proteins as pharmaceutical products Dana Ault Riche, Ph.D., Co-Founder and CEO, Reflexion Pharmaceuticals, USATopic to be submitted			



#### Day two, Thursday, October 29, 2015

8:00-9:00 am	Registration			
SESSION 2	Peptide-based drug discovery and new technologies (continued)			
9:00 am	<b>A novel peptidic CGRP antagonist for the acute treatment of migraine</b> Chris Sores, Ph.D., Founder and President, <i>AcheRx, USA</i>			
9:30 am	<b>Biodegradable microneedle-mediated delivery of anti-GPCR peptides produces effective and safe analgesia on neuropathic pain and neuro inflammatory pain</b> Simon Xie, Ph.D., Founder and CSO, <i>AfaSci Research Laboratories, USA</i>			
10:00 am	<b>The STAMP platform and pipeline programs against C. difficile and other correctable microbial dysbioses</b> Randal Eckert, Ph.D., Senior Director, <i>C3 Jian, Inc., USA</i>			
10:30 am	Coffee break			
10:45 am	<b>Immuno-regulatory antimicrobial peptides and activities</b> Jia Sun (孙嘉), Ph.D., Professor, <i>Jiangnan University(</i> 江南大学), <i>China</i>			
11:15 am	<b>Neuregulin-4: A novel mucosal healing therapeutic for GI disorders</b> Soumitra S. Ghosh, Ph.D., Co-founder & CSO, <i>Avexagen, USA</i>			
11:45 am	<b>Topic to be submitted</b> Ashok Bhandari, Ph.D., Sr. Director of Chemistry, <i>Protagonist Therapeutics, USA</i>			
10.00.000	Lunch break			
12:30-2:00 pm	Lunch break			
SESSION 3	Manufacturing and analytical development for peptide therapeutics			
-				
SESSION 3	Manufacturing and analytical development for peptide therapeutics   Topic to be submitted   David T. Lin, Ph.D., Biologics Consulting Group Inc. (Former Acting			
SESSION 3 2:00 pm	Manufacturing and analytical development for peptide therapeuticsTopic to be submittedDavid T. Lin, Ph.D., Biologics Consulting Group Inc. (Former Acting Division Director of FDA CDER), USAOverview of USP's therapeutic synthetic peptides program Ranjan Chakrabarti, Ph.D., VP, Head-Global Biologics Lab Operations,			
SESSION 3     2:00 pm     2:30 pm	Manufacturing and analytical development for peptide therapeutics   Topic to be submitted   David T. Lin, Ph.D., Biologics Consulting Group Inc. (Former Acting Division Director of FDA CDER), USA   Overview of USP's therapeutic synthetic peptides program   Ranjan Chakrabarti, Ph.D., VP, Head-Global Biologics Lab Operations, United States Pharmacopeia, USA   UPLC analytical method development for peptide therapeutics   Chuanyue Wang (王传跃), Ph.D., President, MHDC Pharmaceuticals			
SESSION 3   2:00 pm   2:30 pm   3:00 pm	Manufacturing and analytical development for peptide therapeuticsTopic to be submitted David T. Lin, Ph.D., Biologics Consulting Group Inc. (Former Acting Division Director of FDA CDER), USAOverview of USP's therapeutic synthetic peptides program Ranjan Chakrabarti, Ph.D., VP, Head-Global Biologics Lab Operations, United States Pharmacopeia, USAUPLC analytical method development for peptide therapeutics Chuanyue Wang (王传跃), Ph.D., President, MHDC Pharmaceuticals Technology (浙江美华鼎昌医药科技有限公司)			
SESSION 3   2:00 pm   2:30 pm   3:00 pm   3:30 pm	Manufacturing and analytical development for peptide therapeuticsTopic to be submittedDavid T. Lin, Ph.D., Biologics Consulting Group Inc. (Former Acting Division Director of FDA CDER), USAOverview of USP's therapeutic synthetic peptides program Ranjan Chakrabarti, Ph.D., VP, Head-Global Biologics Lab Operations, United States Pharmacopeia, USAUPLC analytical method development for peptide therapeutics Chuanyue Wang (王传跃), Ph.D., President, MHDC Pharmaceuticals Technology (浙江美华鼎昌医药科技有限公司)Coffee breakProcess development and large scale cGMP production of Leuprolide Acetate			



#### Day three, Friday, October 30, 2015

8:00-9:00 am	Registration
SESSION 4	Peptide-Based Therapeutics in Clinical Development
9:00 am	<b>PTX-9908. A novel CXCR4 targeting peptide for Liver cancer treatment</b> David Yang, Ph.D., President, <i>MicroConstants, Inc. (China)</i> (北京迈康斯德医药技术有限公司)
9:30 am	<b>Topic to be submitted</b> Vicken Karageozian, MD, Chief Technical Officer, <i>Allegro Ophthalmics</i>
10:00 am	<b>Discovery of peptide agonists for gut GPCRs as therapeutics for type 2 diabetes</b> Ravinder Abrol, Ph.D., Assistant Professor, <i>Cedars-Sinai Medical Center</i>
10:30 am	Coffee break
10:45 am	<b>Global development and commercialization of LMIS 50 mg, a leuprolide</b> <b>6-month depot for the treatment of advanced prostate cancer</b> John Mao, Ph.D., Sr. VP and Head of Development, <i>Foresee Pharmaceuticals, USA</i>
11:15 am	<b>C16G2, the STAMP against S. mutans and dental caries</b> Brian Varnum, Ph.D., Chief Development Officer, <i>C3 Jian, Inc., USA</i>
11:45 am	Wrap up and conclusion
12:30-2:00 pm 2:00-8:00 pm	Lunch break City tour and dinner: Exploring the rich culture, historic relics and natural beauty of City Hangzhou

# **Registration Form**

#### The Third CPC Symposium on Peptide Therapeutics October 28-30, 2015, Hangzhou, China

Personal Information	Personal Information						
Name	Title	Organization	Country				
Address		Telephone	Fax				
Attendence							
□ Speaker							
□ Participant							
□ Student							
Accompany of Speaker/Sponsor/Participant							
Registration Fee							
Full Access		RMB2800 / USD500 (oversea)					
Full Access (Stude	nts)	RMB1400 / USD250 (oversea)					
Meals Only (Accord)	npanies)	RMB1000 / USD200 (oversea)					
Full Access Includes							
✓ Attendance of all for	our sections						
√ Symposium packa	ge						
✓ Lunch, coffee brea	√ Lunch, coffee break						
✓ Reception banque	:						
✓ Sightseeing activity	/						
Meals Only Includes							
✓ Lunch, coffee brea	k						
√ Reception banquet							
√ Sightseeing activity							
Hotel Information							
Check-in Date							
Check-out Date							
Hotel 1	DoubleTree by Hilton Hotel (five stars)						
	□ Single Room: RMB600.00 □ Double Room: RMB600.00						
Hatal 2	Grand New Century Hotel (five stars)						
Hotel 2	🗌 Single Room: RME	3460.00 🗌 Double Room: RI	VB460.00				
Other requirments							
Return this form to ally.wang@chinesepeptide.com or FAX: +86 571 86737113							
For other inquires, please contact: +86 571 86737011							